|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | |||||
| Net income | |||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||
| Depreciation and amortization | |||||
| Amortization of intangible assets | |||||
| Deferred income tax expense | |||||
| Provision for (recovery of) loan losses | |||||
| Provision for credit losses | |||||
| Stock-based compensation expense | |||||
| Net amortization on loan fees, costs, premiums, and discounts | |||||
| Net amortization on securities premiums, discounts, and net unrealized loss on securities transferred to held-to-maturity | |||||
| OTTI gain recognized in earnings | |||||
| Net (income) loss from equity method investments | |||||
| Net loss on sale of securities available for sale and other assets | |||||
| Net (gain) loss on sale of loans and change in fair value on loans held-for-sale | |||||
| Net loss on sale of other real estate owned | |||||
| Net gain on death benefits of bank-owned life insurance | |||||
| Net gain on repurchase of subordinated debt | |||||
| Proceeds from sales of loans held for sale | |||||
| Originations of loans held for sale | |||||
| Increase in cash surrender value of bank-owned life insurance | |||||
| Increase in accrued interest receivable | |||||
| Decrease (increase) in other assets | |||||
| Increase (decrease) in other liabilities | |||||
| Net cash provided by operating activities | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES | |||||
| Net increase in loans | |||||
| Proceeds from sales of loans | |||||
| Purchase of securities available for sale | |||||
| Purchase of securities held-to-maturity | |||||
| Proceeds from sales of securities available for sale | |||||
| Maturities, principal payments and redemptions of securities available for sale | |||||
| Maturities, principal payments and redemptions of securities held-to-maturity | |||||
| Decrease (increase) in resell agreements | |||||
| Decrease (increase) in equity method investments | |||||
| Decrease (increase) in FHLBNY stock, net | |||||
| Purchases of premises and equipment, net | |||||
| Proceeds from redemption of bank-owned life insurance | |||||
| Proceeds from sale of other real estate owned | |||||
| Proceeds from sale of owned assets | |||||
| Net cash used in investing activities | |||||
| CASH FLOWS FROM FINANCING ACTIVITIES | |||||
| Net increase in deposits | |||||
| Increase (decrease) in other borrowings, net | |||||
| Repurchase of subordinated debt | |||||
| Common stock issued under Equity Program | |||||
| Redemption of AREMCO class B shares | |||||
| Repurchase of common stock | |||||
| Dividends paid on common stock | |||||
| Payments related to repurchase of common stock for equity awards | |||||
| Net cash provided by financing activities | |||||
| Increase (decrease) in cash, cash equivalents, and restricted cash | |||||
| Cash, cash equivalents, and restricted cash at beginning of year | |||||
| Cash, cash equivalents, and restricted cash at end of year | |||||
| Supplemental disclosures of cash flow information: | |||||
| Interest paid during the year | |||||
| Income taxes paid during the year | |||||
| Supplemental non-cash activities: | |||||
| Right-of-use assets obtained in exchange for lease liabilities | |||||
| Loans transferred from held-for-sale | |||||
| Loans transferred to other real estate owned | |||||
| Purchase of securities available for sale, net not settled | |||||
| Securities available for sale transferred to held-to-maturity | |||||
| Loans transferred to held-for-sale | |||||
| Cumulative change due to adoption of ASU No. 2016-13 | |||||
Loading...